We got here throughout a bullish thesis on Teva Pharmaceutical Industries Restricted on Kontra Investments’s Substack by Kontra. On this article, we’ll summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries Restricted’s share was buying and selling at $20.21 as of October eighth. TEVA’s trailing and ahead P/E have been 872.00 and seven.06 respectively in response to Yahoo Finance.
Teva Pharmaceutical Industries (TEVA) is rising as a compelling turnaround story, transitioning from a debt-laden generics participant to a targeted branded and specialty firm with momentum in neuroscience. Market exercise underscores this shift, with institutional traders displaying important bullish positioning in October 2025 name choices. Technically, the inventory has recovered previous $20, holding above key shifting averages, signaling a constructive setup.
Central to Teva’s transformation is Ajovy, its anti-CGRP remedy for migraine prevention, which continues to ship regular progress with anticipated quarterly gross sales round $70 million. Ajovy is establishing a sturdy presence in a big and increasing migraine market, benefiting from improved entry dynamics and versatile dosing choices, giving it an extended runway regardless of competitors from Lilly and Amgen.
Much more promising is Teva’s long-acting injectable (LAI) olanzapine program, TEV-749. Section 3 SOLARIS trial knowledge demonstrated sturdy efficacy throughout schizophrenia endpoints and, importantly, no cases of the historic post-injection delirium/sedation syndrome as a result of Teva’s SteadyTeq® expertise. With LAIs at present underpenetrated, TEV-749 alongside UZEDY might seize important market share, doubtlessly producing $1.5–2.0 billion in peak gross sales and reshaping Teva’s branded psychiatry franchise.
Financially, Teva is strengthening, with 2025 revenues projected close to $17 billion, EPS round $2.60, EBIT margins approaching 27%, and free money circulation progress. Internet debt has declined from over $18 billion to roughly $11 billion, with additional deleveraging anticipated, bringing leverage near 1x Internet Debt/EBITDA. Buying and selling at roughly 7x 2025 earnings, Teva gives a uncommon mixture of worth and progress.
With regular efficiency from Ajovy and Austedo and a possible blockbuster in TEV-749, Teva is shifting past its generics legacy. The convergence of pipeline progress, technical power, and enhancing fundamentals positions the inventory for a possible re-rating, making the present value a beautiful entry level for traders looking for each progress and worth.
Beforehand we lined a bullish thesis on Teva Pharmaceutical Industries Restricted (TEVA) by Kontra in Could 2025, which highlighted the corporate’s shift from generics towards branded and specialty medicines, sturdy income progress, and operational enhancements. The corporate’s inventory value has appreciated roughly by 20% since our protection. The thesis nonetheless stands as momentum in neuroscience continues. Kontra emphasizes TEV-749 and technical power as new catalysts.